<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059406</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 702843-CS2</org_study_id>
    <secondary_id>2019-003505-96</secondary_id>
    <nct_id>NCT04059406</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS TMPRSS6-LRx</brief_title>
  <official_title>A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Patients With Non-Transfusion Dependent β-Thalassemia Intermedia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate the efficacy, safety, tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of IONIS TMPRSS6-LRx administered subcutaneously to participants with&#xD;
      non-transfusion dependent β-Thalassemia Intermedia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, open-label study in up to 45 participants. The duration&#xD;
      of each participant in the study will be approximately 29 months and will include an&#xD;
      approximately 2-month screening period, a 24-month treatment period, and a 3-month&#xD;
      post-treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with a ≥ 1.0 grams per deciliter (g/dL) increase from Baseline in hemoglobin (Hb) at Week 27</measure>
    <time_frame>Baseline and Week 27</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a ≥ 1.5 grams per deciliter (g/dL) increase from Baseline in hemoglobin (Hb) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a ≥ 1.0 milligram of iron per gram of dry weight of liver (mg Fe/g) decrease from Baseline in liver iron concentration (LIC) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Beta Thalassemia Intermedia</condition>
  <arm_group>
    <arm_group_label>IONIS TMPRSS6-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of IONIS TMPRSS6-LRx at multiple dose levels, administered subcutaneously every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS TMPRSS6-LRx</intervention_name>
    <description>IONIS TMPRSS6-LRx administered subcutaneously</description>
    <arm_group_label>IONIS TMPRSS6-LRx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willingness to comply with study procedures&#xD;
&#xD;
          -  Clinical diagnosis of Beta-Thalassemia Intermedia with genotypic confirmation&#xD;
&#xD;
          -  Non-transfusion dependent, as defined by: no more than 6 transfusions in the past&#xD;
             12-month period, and no transfusions in the 8-week period prior to Day 1&#xD;
&#xD;
          -  Mean Hb within the range of 6.0-10.0 g/dL, inclusive at Screening&#xD;
&#xD;
          -  LIC within the range of 3.0-20.0 mg Fe/g dry weight, inclusive&#xD;
&#xD;
          -  If using chelators, must be on a stable dose for at least 3 months with LIC &gt; 5.0 mg&#xD;
             Fe/g dry weight and serum ferritin &gt; 300 nanograms per milliliter (ng/mL)&#xD;
&#xD;
          -  Females must be non-pregnant and non-lactating, and either surgically sterile or&#xD;
             postmenopausal&#xD;
&#xD;
          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive&#xD;
             method&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant abnormalities in lab values, medical history, or physical&#xD;
             examination&#xD;
&#xD;
          -  α-globin gene triplication&#xD;
&#xD;
          -  Symptomatic splenomegaly&#xD;
&#xD;
          -  Platelet count &lt; lower limit of normal (LLN) or &gt; 1,000 x 10^9/L&#xD;
&#xD;
          -  Significant concurrent/recent coagulopathy, history of non-traumatic significant&#xD;
             bleeding; history of immune thrombocytopenic purpura (ITP); current use of SC&#xD;
             anti-coagulants; history of thrombotic events, including stroke or DVT&#xD;
&#xD;
          -  Clinically significant renal, liver or cardiac dysfunction&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt; 140 mm Hg systolic or &gt; 90 mm Hg diastolic)&#xD;
&#xD;
          -  Fasting blood glucose &gt; 2.0 × upper limit of normal (ULN)&#xD;
&#xD;
          -  Inability to have a magnetic resonance imaging (MRI) scan&#xD;
&#xD;
          -  Known history or positive test for human immunodeficiency virus (HIV), hepatitis C&#xD;
             (HCV), or hepatitis B (HBV)&#xD;
&#xD;
          -  Active infection requiring systemic antiviral or antimicrobial therapy&#xD;
&#xD;
          -  Regular excessive use of alcohol&#xD;
&#xD;
          -  Recent start of hydroxyurea (6 months prior to Day 1)&#xD;
&#xD;
          -  Treatment with or recent exposure to another investigational drug, biological agent,&#xD;
             ASO, small interfering ribonucleic acid (siRNA), or device within 1 month of&#xD;
             Screening, or 5 half-lives of investigational agent, whichever is longer; or treatment&#xD;
             with or exposure to:&#xD;
&#xD;
               -  sotatercept (ACE-011), luspatercept (ACE-536), or ruxolitinib within 4 months of&#xD;
                  Screening&#xD;
&#xD;
               -  hematopoietic stimulating agents or any hypoxia-inducible factor prolyl&#xD;
                  hydroxylase inhibitors within 8 weeks of Day 1&#xD;
&#xD;
               -  prior bone marrow transplant, stem cell transplant, or gene therapy&#xD;
&#xD;
          -  Surgery associated with significant blood loss within 4 months of Screening,&#xD;
             splenectomy within 12 months of Screening, or splenectomy scheduled during treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>(844) 415-1440</phone>
    <email>ionisNCT04059406study@clinicaltrialmedia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aghia Sophia General Children's Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <state>Peloponnese</state>
        <zip>26 504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koutlimbaneio &amp; Triantafylleio General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>412 21</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ippokrateio (Hippokration) General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chronic Care Center</name>
      <address>
        <city>Hazmiyeh</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thammasat University Hospital</name>
      <address>
        <city>Pathum Thani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Pathum Wan</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Naresuan University Hospital</name>
      <address>
        <city>Phitsanulok</city>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cukurova Üniversitesi Tıp Fakültesi</name>
      <address>
        <city>Adana</city>
        <zip>1330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe Üniversitesi Tıp Fakültesi</name>
      <address>
        <city>Ankara</city>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Faculty of Medicine</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Park Antalya Hastanesi</name>
      <address>
        <city>Antalya</city>
        <zip>07160</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi</name>
      <address>
        <city>İzmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>İstanbul Üniversitesi - Istanbul Tıp Fakültesi</name>
      <address>
        <city>Topkapı</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Greece</country>
    <country>Lebanon</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thalassaemia</keyword>
  <keyword>Beta Thalassemia</keyword>
  <keyword>IONIS TMPRSS6-LRx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

